We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+15.19%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$1.5B
AUM Growth
+$190M
Cap. Flow
+$57.5M
Cap. Flow %
3.83%
Top 10 Hldgs %
78.34%
Holding
38
New
–
Increased
10
Reduced
7
Closed
3

Top Buys

Rank Stock Value
1
ILMN icon
Illumina
ILMN
+$33.3M
2
CDXS icon
Codexis
CDXS
+$18.9M
3
LAB icon
Standard BioTools
LAB
+$14.3M
4
GH icon
Guardant Health
GH
+$7.08M
5
SNDX icon
Syndax Pharmaceuticals
SNDX
+$6.71M

Top Sells

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$12.7M
2
PLRX icon
Pliant Therapeutics
PLRX
+$10.8M
3
DNLI icon
Denali Therapeutics
DNLI
+$7.68M
4
VCYT icon
Veracyte
VCYT
+$5.39M
5
KYTX icon
Kyverna Therapeutics
KYTX
+$4.31M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLFS icon
1
BioLife Solutions
BLFS
$1.56B
$218M 14.54%
8,707,165
– –
RVMD icon
2
Revolution Medicines
RVMD
$38.8B
$187M 12.44%
4,114,283
-292,592
-7% -$12.7M
WGS icon
3
GeneDx Holdings
WGS
$1.98B
$149M 9.92%
3,507,164
-19,247
-0.5% -$650K
LAB icon
4
Standard BioTools
LAB
$343M
$138M 9.17%
71,254,677
+7,295,000
+11% +$14.3M
SRPT icon
5
Sarepta Therapeutics
SRPT
$1.63B
$134M 8.94%
1,073,500
– –
ILMN icon
6
Illumina
ILMN
$30.2B
$97.8M 6.52%
750,000
+270,000
+56% +$33.3M
RNAM
7
DELISTED
Avidity Biosciences
RNAM
$95.8M 6.38%
2,084,841
– –
RLAY icon
8
Relay Therapeutics
RLAY
$4.04B
$65.5M 4.37%
9,251,108
+802,534
+9% +$6M
ALNY icon
9
Alnylam Pharmaceuticals
ALNY
$29.1B
$46.8M 3.12%
170,000
– –
EXAS
10
DELISTED
Exact Sciences
EXAS
$44.3M 2.95%
650,000
– –
NTLA icon
11
Intellia Therapeutics
NTLA
$1.5B
$41.1M 2.74%
2,000,000
– –
GPCR icon
12
Structure Therapeutics
GPCR
$3.39B
$30.7M 2.05%
700,000
– –
BPMC
13
DELISTED
Blueprint Medicines
BPMC
$30.2M 2.01%
326,378
– –
DNLI icon
14
Denali Therapeutics
DNLI
$3.67B
$28.8M 1.92%
990,000
-310,000
-24% -$7.68M
CDXS icon
15
Codexis
CDXS
$157M
$24.9M 1.66%
8,100,000
+6,100,000
+305% +$18.9M
VCYT icon
16
Veracyte
VCYT
$3.6B
$22.7M 1.51%
666,308
-191,596
-22% -$5.39M
NGNE icon
17
Neurogene
NGNE
$657M
$22M 1.47%
524,616
– –
VERV
18
DELISTED
Verve Therapeutics
VERV
$19.3M 1.29%
3,995,571
+936,477
+31% +$5.44M
BEAM icon
19
Beam Therapeutics
BEAM
$2.66B
$19M 1.27%
775,000
+100,000
+15% +$2.58M
TNYA icon
20
Tenaya Therapeutics
TNYA
$161M
$13M 0.87%
6,732,971
– –
FDMT icon
21
4D Molecular Therapeutics
FDMT
$524M
$12.4M 0.83%
1,150,000
+350,000
+44% +$5.81M
TSVT
22
DELISTED
2seventy bio
TSVT
$9.44M 0.63%
2,000,000
– –
TNGX icon
23
Tango Therapeutics
TNGX
$4.43B
$9.15M 0.61%
1,188,349
– –
SNDX icon
24
Syndax Pharmaceuticals
SNDX
$1.69B
$9.14M 0.61%
475,000
+325,000
+217% +$6.71M
GH icon
25
Guardant Health
GH
$21.6B
$8.03M 0.54%
350,000
+250,000
+250% +$7.08M
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MIM
Marco Investment Management Atlanta, Georgia $1.33B AUM 32.43% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
MCM
Mill Capital Management Concord, North Carolina $1.31B AUM 17.4% 1-Year Est. Return
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return

Casdin Capital's Q3 2024 Portfolio in Review

As of Q3 2024, Casdin Capital held 38 positions worth $1.5B, up 15% from $1.31B the previous quarter. Its ten largest holdings account for 78% of the portfolio.

Casdin Capital deployed $57.5M of net new capital in Q3 2024, adding to 10 existing holdings.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Revolution Medicines, an estimated $12.7M trimmed.

  • Casdin Capital added most to Illumina in Q3 2024, an estimated $33.3M increase.
  • Casdin Capital's biggest Q3 2024 reduction was Revolution Medicines, cutting an estimated $12.7M.
  • Casdin Capital fully exited Pliant Therapeutics in Q3 2024, selling an estimated $10.8M.
  • Casdin Capital's ten largest holdings make up 78% of its $1.5B portfolio in Q3 2024.
  • Casdin Capital opened 0 new positions and closed 3 in Q3 2024.
  • Casdin Capital's portfolio value rose 15% quarter-over-quarter to $1.5B.

Based on Casdin Capital's 13F filing for Q3 2024, filed 14 Nov 2024.